Reactive yellow 3 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.

REC114 Human Pre-designed siRNA Set A contains three designed siRNAs for REC114 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REC8 Human Pre-designed siRNA Set A contains three designed siRNAs for REC8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RECK Human Pre-designed siRNA Set A contains three designed siRNAs for RECK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Recombinant endoglycoceramidase I (rEGCase I) is a glycosidase that catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides. Recombinant endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of glycosphingolipids (GSLs) to the primary hydroxyl group of several 1-alkanols[1].

Recombinant endoglycoceramidase I assisted by activator II (rEGCase I assisted by Activator II) is a mixture-form of EGCase I and Activator II. EGCase I is a glycolipid-specific hydrolase that well-suited to a comprehensive analysis of glycosphingolipids (GSLs). Activator II is capable of inducing activity of EGCase without any detergent reagents[1][2].

Recombinant endoglycoceramidase II (rEGCase II) is an endo-β-glucosidase releasing the complete glycan from ceramide in glycosphingolipids. Recombinant endoglycoceramidase II catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids[1][2].

RECQL Human Pre-designed siRNA Set A contains three designed siRNAs for RECQL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RECQL4 Human Pre-designed siRNA Set A contains three designed siRNAs for RECQL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RECQL5 Human Pre-designed siRNA Set A contains three designed siRNAs for RECQL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Red Fluorescent Gelatin Methacryloyl (Red Fluorescent GelMA) is methacryloyl gelatin (GelMA) with green fluorescence, which is obtained by “grafting” fluorescent molecules on GelMA. Red Fluorescent Gelatin Methacryloyl acts as a scaffold and can be used to engineer tissue analogs from the vasculature to cartilage and bone, allowing cells to proliferate and spread. Red Fluorescent Gelatin […]

REEP1 Human Pre-designed siRNA Set A contains three designed siRNAs for REEP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REEP2 Human Pre-designed siRNA Set A contains three designed siRNAs for REEP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REEP3 Human Pre-designed siRNA Set A contains three designed siRNAs for REEP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REEP5 Human Pre-designed siRNA Set A contains three designed siRNAs for REEP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REEP6 Human Pre-designed siRNA Set A contains three designed siRNAs for REEP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REG1A Human Pre-designed siRNA Set A contains three designed siRNAs for REG1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REG1B Human Pre-designed siRNA Set A contains three designed siRNAs for REG1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REG3A Human Pre-designed siRNA Set A contains three designed siRNAs for REG3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REG3G Human Pre-designed siRNA Set A contains three designed siRNAs for REG3G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REG4 Human Pre-designed siRNA Set A contains three designed siRNAs for REG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

REL Human Pre-designed siRNA Set A contains three designed siRNAs for REL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rel Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rel gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rel Rat Pre-designed siRNA Set A contains three designed siRNAs for Rel gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride is the deuterium labeled rel-(1S,2R)-Dihydro bupropion hydrochloride[1].

rel-4(5)-Epdpe methyl ester is a rel-4(5)-Epdpe derivative.

rel-Erteberel is rel isomer of Erteberel (HY-18295). Erteberel is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Erteberel has anti-tumor activities[1][2].

rel-Hydroxycotinine-d3 is deuterated labeled Hydroxycotinine (HY-113239). Hydroxycotinine is the main nicotine metabolite detected in smokers urine.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.

RELA Human Pre-designed siRNA Set A contains three designed siRNAs for RELA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rela Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rela gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rela Rat Pre-designed siRNA Set A contains three designed siRNAs for Rela gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.

Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.

Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.

Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.

Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.

Relaxin H3 (human) (TFA) is a kind of relaxin peptide. Relaxin H3 (human) (TFA) exerts antifibrotic actions via RXFP1[1].

RELB Human Pre-designed siRNA Set A contains three designed siRNAs for RELB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Relb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Relb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Relb Rat Pre-designed siRNA Set A contains three designed siRNAs for Relb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.